arrow
G

Gniewomir Latacz

Jagiellonian University
H指数:27
被引数:2,385

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interactions between SSR504734, a selective glycine transporter type 1 inhibitor, and antiseizure drugs: pharmacodynamic and pharmacokinetic studies in mice

SSR504734(一种选择性甘氨酸转运体1型抑制剂)与抗惊厥药物之间的相互作用:小鼠的药效学和药代动力学研究

2026-09-290
PRE
L-carnosine as a biocompatible dipeptide carrier for oral delivery of amorphous bosentan: the ternary systems loaded with a new grade of poly(acrylic acid), hypromellose or copovidone

L-肌肽作为一种生物相容性二肽载体用于无定形波生坦的口服递送:负载一种新型聚丙烯酸、羟丙甲纤维素或考比替代的二元体系

2026-07-010
PRE
Novel 3-Methoxypropanamide Derivatives as Potential Antiseizure and Antinociceptive Agents: Experimental Evidence from In Vitro and In Vivo Studies

新型3-甲氧基丙酰胺衍生物作为潜在的抗惊厥和镇痛剂:体外和体内研究的实验证据

2026-05-010
PRE
Chemical modification of STL427944 toward morpholine-based 1,3,5-triazines as anticancer agents targeting FOXM1: green synthesis, biological evaluation and ADME-Tox profiling in a colorectal cancer model

STL427944的化学修饰及其作为靶向FOXM1的抗癌剂应用于吗啉基1,3,5-三嗪类化合物:绿色合成、生物评价及在结直肠癌模型中的ADME-Tox分析

2025-12-290
PRE
Discovery of novel hybrid pyrrolidin-2-one derivatives exhibiting potent antiseizure and antinociceptive effects in preclinical models

发现具有显著抗惊厥和镇痛作用的全新杂环吡咯烷-2-酮衍生物,在临床前模型中展现出效果。

2025-11-010
OAAI
Novel Dual 5-HT7 Antagonists and Sodium Channel Inhibitors as Potential Therapeutic Agents with Antidepressant and Anxiolytic Activities

新型双5-HT7拮抗剂和钠通道抑制剂作为具有抗抑郁和抗焦虑活性的潜在治疗药物

2025-10-020
OAAI
The first-in-class 1,3,5-triazine-derived dual 5-HT6R/FAAH modulators in search for potential drug against neurodegenerative diseases with cognitive impairment

第一类1,3,5-三嗪衍生的双5-HT6R/FAAH调节剂,用于寻找针对伴有认知障碍的神经退行性疾病的潜在药物

2025-08-050
OA
Effect of SSR504734, a Selective Glycine Transporter Type 1 Inhibitor, on Seizure Thresholds, Neurotransmitter Levels, and Inflammatory Markers in Mice

SSR504734(一种选择性甘氨酸转运体1型抑制剂)对小鼠惊厥阈值、神经递质水平和炎症标志物的影响

2025-02-260
OA
Multifunctional, Fluorene-Based Modulator of Cholinergic and GABAergic Neurotransmission as a Novel Drug Candidate for Palliative Treatment of Alzheimer's Disease
2024-11-220
OA
Discovery and Profiling of New Multimodal Phenylglycinamide Derivatives as Potent Antiseizure and Antinociceptive Drug Candidates
2024-08-211
OAAI
Exploring Novel GSK-3β Inhibitors for Anti-Neuroinflammatory and Neuroprotective Effects: Synthesis, Crystallography, Computational Analysis, and Biological Evaluation
2024-08-190
OAAI
Potent, Selective Agonists for the Cannabinoid-like Orphan G Protein-Coupled Receptor GPR18: A Promising Drug Target for Cancer and Immunity
2024-06-170
PRE
Novel Alaninamide Derivatives with Drug-like Potential for Development as Antiseizure and Antinociceptive Therapies-In Vitro and In Vivo Characterization
2024-05-141
OAAI
First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT6 Agents with a Beneficial Neuroprotective Profile against Alzheimer's Disease
2024-01-089
OAAI